Study on Early Use of PCSK9 Inhibitors for Intensive Lipid-Lowering in Chinese Patients With Acute Coronary Syndrome During Hospital Stay

What this Trial Is About

Researchers are evaluating the impact of starting PCSK9 inhibitor therapy early during hospitalization in Chinese patients with acute coronary syndrome ACS. The study aims to see if this approach improves the rate of reaching recommended lipid levels, shortens the time to meet these goals within one year, and reduces adverse cardiovascular events. Three lipid-lowering strategies will be compared PCSK9 inhibitors with or without statins EzetimibeHybutimibe, statin plus EzetimibeHybutimibe, and statin alone. Participants will receive one of the three treatments PCSK9 inhibitor therapy every two weeks with or without daily statins EzetimibeHybutimibe, daily statin plus EzetimibeHybutimibe therapy, or daily statin monotherapy. Treatment adjustments during follow-up depend on the physicians decisions and patient preferences. Follow-up visits will monitor laboratory indicators at baseline, 3 days after admission, at hospital discharge 5 to 10 days after admission, and at 1, 3, 6, and 12 months after discharge. During the study, participants will undergo blood tests to assess lipid levels and inflammatory markers at various time points. Researchers will track the occurrence of major adverse cardiovascular events over 12 months. The primary outcome is the lipid attainment rate at each visit, while secondary outcomes include time to reach lipid goals, incidence of cardiovascular events, and changes in LDL cholesterol and inflammatory factors. The total follow-up duration for each participant is 12 months.

Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)